Biotech Archives - Page 82 of 795

2 minute read

eFFECTOR Therapeutics Announces Topline Results Of Phase 2 KICKSTART Trial Of Tomivosertib Combined With Pembrolizumab In Non-Small Cell Lung Cancer

April 4, 8:32 AM

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced topline results from the primary analysis of the

EFTR

3 minute read

Tempest Announces Publication Of Data From Phase 1 Trial Of TPST-1120 In Patients With Advanced Solid Tumors In Journal Of Cancer Research Communications

By Benzinga Newsdesk

April 4, 8:10 AM

TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized data, Company preparing to

TPST

3 minute read

Candel Therapeutics Announces Interim Data From Randomized Phase 2 Clinical Trial Of CAN-2409 In Non-Metastatic Pancreatic Cancer

By Benzinga Newsdesk

April 4, 8:04 AM

Updated positive interim data showed notable improvements in estimated median overall survival of 28.8 months after experimental treatment with CAN-2409 versus only 12.5 months in control group in borderline resectable

CADL

2 minute read

Biora Therapeutics Achieves Interim Results For Clinical Trial Of BT-600, Advancing NaviCap Platform Development

By Benzinga Newsdesk

April 4, 8:04 AM

All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon All NaviCap™ devices performed as intended and were well tolerated, with no safety

BIOR

2 minute read

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions In Patients With Diabetes

By Benzinga Newsdesk

April 4, 8:02 AM

Atherosclerosis (AS) and its sequelae are the most common cause of death in diabetic patients and one of the reasons why diabetes has entered the top 10 causes of death worldwide.The published data show that inhibiting

ZVSA

2 minute read

DMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial Design

By Lara Goldstein

April 3, 4:45 PM

Canadian clinical-stage biotech company Algernon Pharmaceuticals (OTCQB:AGNPF) announced its plans to move forward with an intravenous (IV) formulation…

AGNPF

2 minute read

Novo Nordisk’s Popular Diabetes Drug Ozempic Starter Kits Face Extended Shortages in Germany, Faces Biosimilar Threat In China

By Vandana Singh

April 3, 1:37 PM

Novo Nordisk warns of Ozempic starter kit scarcity in Germany amid ongoing supply challenges in Europe. Restrictions on off-label use emphasized, with intermittent shortages expected in 2024. Biosimilar Jiyoutai awaits approval in China. FDA tightens Mounjaro supply due to high demand.

LLY

2 minute read

FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape

By Vandana Singh

April 3, 10:02 AM

FibroGen reveals Phase 1 results for FG-3246 for metastatic castration-resistant prostate cancer. Promising efficacy metrics and plans for enhanced therapeutic strategies signal potential advancements in treatment. Learn more about this groundbreaking development."

ABBV

1 minute read

Small-Cap ARCA Biopharma Stock Soars On Merger Pact: The Details

By Vandana Singh

April 3, 10:00 AM

ARCA Biopharma and Oruka Therapeutics merge, focusing on novel biologics for chronic skin diseases like plaque psoriasis. ORKA-001 and ORKA-002 advance, supported by $275 million investment. Expect clinical trials in 2025. Merger closes Q3 2024. ABIO shares up 81.3% premarket."

ABIO

3 minute read

Ligand Pharmaceuticals Announces Launch Of Pelthos Therapeutics To Accelerate Commercialization Of ZELSUVMI, Scott Plesha Named CEO

By Benzinga Newsdesk

April 3, 9:05 AM

Pharmaceutical executive Scott Plesha named CEOLead product ZELSUVMI expected to be commercially available in late 2024Ligand Pharmaceuticals (NASDAQ:LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a

LGND